Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 10/20 | 1.00 |
| ▸ | PLG | P00747 | 4/20 | 1.00 |
| ▸ | KLK8 | O60259 | 3/20 | 1.00 |
| ▸ | F2 | P00734 | 3/20 | 1.00 |
| ▸ | F10 | P00742 | 3/20 | 1.00 |
| ▸ | PLAT | P00750 | 3/20 | 1.00 |
| ▸ | KLK4 | Q9Y5K2 | 3/20 | 1.00 |
| ▸ | KLK1 | P06870 | 3/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | KLK2 | P20151 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297455 | 1.00 | PLAU (1.00) | PLAUPLGKLK8F2F10 | |
| Hydrochloric Acid SCHEMBL7390446 | 0.99 | PLAU (0.98) | PLAUPLGKLK8F2F10 | |
| Hydrochloric Acid SCHEMBL7393506 | 0.93 | PLAU (0.87) | PLAUPLGKLK8F2F10 | |
| Hydrochloric Acid SCHEMBL7386655 | 0.92 | PLAU (0.85) | PLAUPLGKLK8F2F10 | |
| SCHEMBL1364942 | 0.91 | PLAU (0.83) | PLAUPLGKLK8F2F10 | |
| Hydrochloric Acid SCHEMBL7390732 | 0.90 | PLAU (0.81) | PLAUPLGKLK8F2F10 | |
| SCHEMBL17126717 | 0.88 | PLAU (0.78) | PLAUPLGKLK8F2F10 | |
| SCHEMBL2240660 | 0.87 | PLAU (0.77) | PLAUPLGKLK8F2F10 | |
| SCHEMBL17126245 | 0.87 | KLK1 (0.83) | PLAUPLGKLK8F2F10 | |
| Hydrochloric Acid SCHEMBL7387935 | 0.86 | PLAU (0.75) | PLAUPLGKLK8F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615946-B1 | PROTEOLYTIC AND COVALENT ANTIBODIES | PAUL SUDHIR (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9006388-B2 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent | Paul, Sudhir (US) | 2015-04-14 | — | — | US | disclosed |
| US-8980646-B2 | Proteolytic and covalent antibodies | PAUL, SUDHIR (US) | 2015-03-17 | — | — | US | disclosed |
| US-20090297534-A1 | Catalytic Immunoglobulins BBK32 and Uses Therefor | PAUL SUDHIR | 2009-12-03 | — | — | US | disclosed |
| EP-1907423-A2 | CATALYTIC IMMUNOGLOBULINS | Coimmune Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070179083-A1 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding | COVALENT BIOSCIENCE INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070105092-A1 | Proteolytic and covalent antibodies | COVALENT BIOSCIENCE INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| WO-2007011639-A2 | CATALYTIC IMMUNOGLOBULINS | COIMMUNE INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| EP-1610808-A2 | COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING | University of Texas Medical School (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087059-A2 | COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING | THE UNIVERSITY OF TEXAS (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179083-A1 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding | FABP1, FPR1, ADGRF1 | PLAU 3231/4885PLG 1692/4885KLK8 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.